An observational study in Crohn Disease, sponsored by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Observational
Among 22 studies in Crohn Disease by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives — 5 open to participants now, 6 under way, none of them phase 3. Crohn Disease · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.
Among the 22 studies in Crohn Disease by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, this one is the only one that started in 2023, is one of 6 observational ones, and was the 16th registered.
1,992 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
This study's enrollment of 320 is above the median of 185 across 645 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →5 of the 22 studies in Crohn Disease by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives are open now, in 1 country. Each count lists the studies.
Of the 354 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 96 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2023.
Median enrollment 114 across the 16 interventional studies, 460 across the 6 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives is the lead sponsor of 35 studies on the registry; 7 are open to participants now.
2 of the studies in Crohn Disease by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06742385Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEvaluation of a Remote Monitoring Application in the Follow-up of Patients With Active Inflammatory Bowel Diseases | 2027-09-18 |
| NCT07292012Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEfficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | 2027-11 |
Among the 22 studies in Crohn Disease by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, from their registry updates:
Multicenter prospective cross-sectional study of CD patients, its aim is the construction of an objective and reproducible system for evaluation of Transmural healing in Crohn's Disease (CD).
Primary objective : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
Number of patients : 210 patients, in 14 sites (only one investigator per site), 15 patients per site, 5 patients per grade of transmural healing based on the appraisal of a local reader pair (a gastroenterologist and a radiologist).
Recruitment period : 2 years
Primary Endpoint : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
Secondary Endpoints :
The criteria were revised on the registry on Nov 4, 2026. See what changed
Patients diagnosed with CD for more than 6 months with histological confirmation available in his medical record, with an indication for MRE based on routine clinical practice validated by the treating physician
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
An index (depth of remission) or score (grade of remission) will be constructed through multiple linear or logistic mixed regression models.
Time frame: Day 1
Intra- and inter-observer variability of lesions observed per segment during MRE in CD
Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.
Time frame: Day 1
Intra- and inter-observer variability of depth and grade of global transmural healing in CD
Variations in MRE readings images between the CR will be quantified through the Kappa coefficient for qualitative items and through the intraclass correlation coefficient for quantitative items.
Time frame: Day 1
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives